Inflammatory arthritis during immune checkpoint inhibitors therapy: case report
Abstract
Nowadays, technological and scientific developments in modern medicine have enabled the emergence of new treatment strategies in the treatment of solid and hematologic malignancies. One group of these developments is, also called cancer immunotheraphy, Immune Checkpoint Inhibitors (ICI) thatareused in laterstages of tumors. ICI’s are monoclonal antibodies that allow cancercells to be killed by natural and adaptive immunity, especially T lymphocytes via activation or inhibition of the co-receptors. However, cancer immunotherapy can lead to activation of the immunecells to host’s healthy cells by eliminating self-tolerance, and to start series of immune reactions. Here, we aimed to present a case of inflammatory arthritis during cancer immunotherapy.
Keywords
References
- Duzgun O, Sarici IS, Gokcay S, et al. Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model. Acta Cir Bras 2017;32(12):1006-12.
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30.
- Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
- GirouxLeprieur E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer 2017;78:16-23.
- Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158-68.
- Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immunecheckpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95. doi: 10.1186/s40425-017-0300-z.
- Teixidor E, Sais E, Vásquez CA, at al. Immune-related adverse events and atypical radiological response with checkpoint inhibitör immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget 2018;9(68):33043-9.
- Cappelli LC, Gutierrez AK, Baer AN, at al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76(1):43-50.
Details
Primary Language
Turkish
Subjects
-
Journal Section
Other
Authors
Tuncer Şak
*
0000-0001-6366-7038
Türkiye
Burçak Karaca
0000-0003-2638-1625
Türkiye
Figen Yargucu Zihni
0000-0001-7479-3582
Türkiye
Publication Date
October 25, 2019
Submission Date
October 19, 2018
Acceptance Date
August 15, 2019
Published in Issue
Year 1970